ALPN — Alpine Immune Sciences Share Price
0.000.00%
Last trade - 00:00- $4.46bn
- $4.15bn
- $58.88m
- 56
- 12
- 79
- 47
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 13.4 | ||
| Price to Tang. Book | 13.4 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 78.85 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -15.04% | ||
| Return on Equity | -14.67% | ||
| Operating Margin | -90.86% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.74 | 9.34 | 23.44 | 30.06 | 58.88 | 17.33 | 9.87 | 142.3% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company, which is engaged in discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. The Company’s approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its ALPN-303 (povetacicept) is a dual antagonist of the B cell activating factor (BAFF) and a proliferation, inducing ligand (APRIL), cytokines, which play key roles in the pathogenesis of multiple autoimmune diseases via their contribution to the activation, differentiation and/or survival of B cells, particularly antibody-secreting cells, as well as T cells and innate immune cells. Its ALPN-101 (acazicolcept) is a dual Inducible T cell Costimulator (ICOS), and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.
Directors
- Mitchell Gold CHM (54)
- Stanford Peng PRE (50)
- Paul Rickey CFO (42)
- Jay Venkatesan DRC (49)
- Robert Conway IND (67)
- Xiangmin Cui IND (52)
- Natasha Hernday IND (49)
- Christopher Peetz IND (42)
- Peter Thompson IND (61)
- James Topper IND (59)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- March 30th, 2007
- Public Since
- June 17th, 2015
- No. of Shareholders
- 24
- No. of Employees
- 142
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 68,597,527
- Address
- 188 East Blaine St., Suite 200, SEATTLE, 98102
- Web
- https://www.alpineimmunesciences.com/
- Phone
- +1 2067884545
- Contact
- Temre Johnson
- Auditors
- Ernst & Young LLP
Upcoming Events for ALPN
Q2 2024 Alpine Immune Sciences Inc Earnings Release
Q3 2024 Alpine Immune Sciences Inc Earnings Release
Similar to ALPN
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Alpine Immune Sciences share price?
As of Today at 13:51 UTC, shares in Alpine Immune Sciences are trading at $64.97. This share price information is delayed by 15 minutes.
How has the Alpine Immune Sciences share price performed this year?
Shares in Alpine Immune Sciences last closed at $64.97 and the price had moved by +655.47% over the past 365 days. In terms of relative price strength the Alpine Immune Sciences share price has outperformed the S&P500 Index by +496.7% over the past year.
What are the analyst and broker recommendations for Alpine Immune Sciences?
The overall consensus recommendation for Alpine Immune Sciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Alpine Immune Sciences dividend yield?
Alpine Immune Sciences does not currently pay a dividend.
Does Alpine Immune Sciences pay a dividend?
Alpine Immune Sciences does not currently pay a dividend.
When does Alpine Immune Sciences next pay dividends?
Alpine Immune Sciences does not currently pay a dividend.
How do I buy Alpine Immune Sciences shares?
To buy shares in Alpine Immune Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Alpine Immune Sciences?
As of the previous close price of $64.97, shares in Alpine Immune Sciences had a market capitalisation of $4.46bn.
Where are Alpine Immune Sciences shares listed?
Here are the trading details for Alpine Immune Sciences:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ALPN
What kind of share is Alpine Immune Sciences?
Based on an overall assessment of its quality, value and momentum Alpine Immune Sciences is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Alpine Immune Sciences share price forecast for 2024?
The analyst consensus target price for shares in Alpine Immune Sciences is $62.00. That is 4.57% below the last closing price of $64.97.
Analysts covering Alpine Immune Sciences currently have a consensus Earnings Per Share (EPS) forecast of -$1.46 for the next financial year.
Find out moreWhat is the trend in the Alpine Immune Sciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Alpine Immune Sciences. Over the past six months, its share price has outperformed the S&P500 Index by +317.08%.
As of the last closing price of $64.97, shares in Alpine Immune Sciences were trading +147.28% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Alpine Immune Sciences PE Ratio?
The Alpine Immune Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $64.97.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Alpine Immune Sciences?
Alpine Immune Sciences' management team is headed by:
- Mitchell Gold - CHM
- Stanford Peng - PRE
- Paul Rickey - CFO
- Jay Venkatesan - DRC
- Robert Conway - IND
- Xiangmin Cui - IND
- Natasha Hernday - IND
- Christopher Peetz - IND
- Peter Thompson - IND
- James Topper - IND